A specialty pharma firm commercializing novel therapies for rare diseases with significant revenue growth but persistent net losses driven by R&D and operating expenses.
Investors may consider MIRM attractive due to its rapid top-line growth trajectory which has more than doubled annually over the last three years, signaling strong product demand. The company's cash position of nearly $300M offers a substantial runway to invest in pipeline expansion without immediate dilution from equity issuances. Success in rare disease markets often translates to high-margin revenue streams that can support profitability once sales volume scales significantly.
The persistent net loss and negative operating profit of $22.1M highlight the company's current inability to convert revenue into sustainable earnings, posing a long-term valuation challenge. High accounts payable and accrued expenses relative to revenue suggest potential liquidity pressure or aggressive working capital management that warrants scrutiny. Without a clear path to breakeven, the stock remains speculative and vulnerable to market corrections in biotech sectors.
Mirum Pharmaceuticals (MIRM) is a specialty pharmaceutical company focused on developing and commercializing novel therapies primarily for rare diseases and orphan indications. The company serves global markets with a portfolio centered on high-value, low-volume treatments that address unmet medical needs in niche therapeutic areas. Key products include proprietary drugs targeting conditions such as primary ciliary dyskinesia and other rare genetic disorders.
Mirum Pharmaceuticals demonstrated substantial revenue growth, increasing from $77.1M in 2022 to $521.3M in 2025, reflecting successful market penetration and commercial execution. However, the company continues to report net losses, which narrowed from a deficit of $163.4M in 2023 to $23.4M in 2025, suggesting improving operational efficiency despite high operating expenses of $543.4M. The balance sheet remains robust with cash and equivalents of $296.7M and total current assets of $549.7M, providing ample liquidity to fund operations and potential strategic acquisitions.
The specialty pharmaceutical industry is characterized by high barriers to entry driven by complex regulatory approval processes for orphan drugs and stringent clinical trial requirements. Market dynamics favor companies with differentiated products that solve critical unmet needs, as competition from large generic manufacturers is typically absent in these niche segments. Pricing power is often maintained through government-backed exclusivity periods and the lack of therapeutic alternatives for patients with rare conditions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $77.1M | $186.4M | $336.9M | $521.3M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $77.1M | $186.4M | $336.9M | $521.3M |
| Operating Expenses | $208.3M | $295.5M | $424.5M | $543.4M |
| Operating Income | $-131.2M | $-109.2M | $-87.6M | $-22.1M |
| G&A | $89.1M | $145.9M | $202.2M | $257.0M |
| Stock-Based Comp | $27.0M | $35.0M | $48.4M | $71.4M |
| D&A | $3.2M | $10.8M | $23.6M | $24.2M |
| Amortization | $2.9M | $10.5M | $23.1M | $23.9M |
| Other OpEx | $119.2M | $149.6M | $222.3M | $286.4M |
| Non-Operating Income | $-10.9M | $-53.3M | $694.0K | $709.0K |
| Interest Income | $3.9M | $13.7M | $13.8M | $12.7M |
| Pre-Tax Income | $-142.1M | $-162.4M | $-86.9M | $-21.4M |
| Income Tax | $-6.4M | $991.0K | $1.0M | $1.9M |
| Continuing Ops | $-135.7M | $-163.4M | $-87.9M | $-23.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-135.7M | $-163.4M | $-87.9M | $-23.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-135.7M | $-163.4M | $-87.9M | $-23.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $190.2M | $387.5M | $392.8M | $549.7M |
| Cash & Equivalents | $28.0M | $286.3M | $222.5M | $296.7M |
| Marketable Securities | $123.7M | $0 | $57.8M | $86.6M |
| Accounts Receivable | $24.0M | $68.0M | $78.3M | $123.3M |
| Inventory | $5.6M | $22.3M | $22.4M | $24.9M |
| Prepaid Expenses | $8.9M | $10.9M | $11.8M | $18.1M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $162.7M | $259.1M | $278.0M | $293.1M |
| PP&E (Net) | $914.0K | $706.0K | $1.1M | $1.9M |
| Intangibles | $59.0M | $252.9M | $249.8M | $260.9M |
| Operating Leases | $1.4M | $1.3M | $8.7M | $8.7M |
| LT Investments | $0 | — | $12.5M | $8.1M |
| Other LT Assets | $101.4M | $4.2M | $5.8M | $13.5M |
| Total Assets | $352.9M | $646.6M | $670.8M | $842.8M |
| Current Liabilities | $64.7M | $87.1M | $126.6M | $205.8M |
| Accounts Payable | $8.7M | $7.4M | $14.6M | $9.6M |
| Current Leases | $931.0K | $1.1M | $1.7M | $2.1M |
| Other Current Liab | $1.1M | $0 | $0 | $-2.1M |
| Long-Term Liabilities | $146.1M | $310.9M | $318.6M | $322.3M |
| LT Operating Leases | $1.3M | $617.0K | $8.0M | $7.5M |
| Other LT Liab | $144.9M | $310.3M | $310.6M | $314.8M |
| Total Liabilities | $210.9M | $398.0M | $445.1M | $528.1M |
| Shareholders' Equity | $142.0M | $248.7M | $225.6M | $314.7M |
| Retained Earnings | $-392.8M | $-556.2M | $-644.2M | $-667.5M |
| AOCI | $-217.0K | $1.6M | $-373.0K | $351.0K |
| Total L&E | $352.9M | $646.6M | $670.8M | $842.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-135.7M | $-163.4M | $-87.9M | $-23.4M |
| Non-Cash Adjustments | $-11.7M | $40.9M | $82.1M | $13.2M |
| Working Capital Changes | $27.3M | $51.5M | $16.2M | $66.0M |
| Cash from Operations | $-120.1M | $-70.9M | $10.3M | $55.8M |
| Capital Expenditures | $278.0K | $109.0K | $993.0K | $954.0K |
| Cash from Investing | $7.7M | $-107.2M | $-90.1M | $-24.0M |
| Cash from Financing | $109.1M | $336.6M | $17.7M | $40.1M |
| FX Effect | $12.0K | $-133.0K | $-1.3M | $3.2M |
| Net Change in Cash | $-3.3M | $158.3M | $-63.4M | $75.2M |
| Beginning Cash | $131.3M | $128.0M | $286.3M | $222.9M |
| Ending Cash | $128.0M | $286.3M | $222.9M | $298.2M |
The company's revenue is derived from the sale of its proprietary drug products, specifically Mirum Pharmaceuticals' approved therapies for orphan indications. Revenue streams are concentrated in specialized markets where competition is limited due to high regulatory barriers and specific patient populations. The business model relies on commercializing a small number of high-margin products rather than broad blockbuster drugs.
The company faces significant revenue concentration risk as its total revenue is heavily dependent on a limited number of product lines and specific geographic markets. Persistent net losses of $23.4M in 2025 indicate ongoing burn rates that could deplete cash reserves if sales do not accelerate or new products are not approved. Regulatory uncertainties regarding orphan drug exclusivity extensions or pricing caps could materially impact future profitability margins. Dependence on third-party manufacturing partners introduces supply chain and quality control risks that could disrupt product availability.
Mirum possesses strong intellectual property protection through a robust patent portfolio that secures exclusive rights to its novel therapies for extended periods. The company benefits from a specialized sales force deeply knowledgeable about rare disease management, enabling effective patient access and support in fragmented markets. Its focus on orphan drugs allows it to command premium pricing structures supported by government incentives and lack of direct generic competition.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.